|
p:
415-206-6640
f: 415-648-8425
e: imboden@itsa.ucsf.edu
University
of California, San Francisco
1001 Potrero Ave., SFGH 30-3300
Box 0868
San Francisco, CA 94143-0868
Dr.
Imboden received his MD from Johns Hopkins University in 1977, where
he also completed his Internship and Residency (1977-80). He completed
his Rheumatology Fellowship at the University of California, San
Francisco (1981-84).
Other Experience and Professional Memberships
1980: American Board of Internal Medicine
1985: American Board of Rheumatology
1987 - 91: Associate Editor, Journal of Immunology
1991 - 93: Member, Basic Immunology Study Section, Arthritis Foundation
1992 - 95: Member, Immunology Study Section, VA Merit Review Board
1993: American Society for Clinical Investigation
1994: Chairman, Molecular Immunology Study Section, Arthritis Foundation
1993- 98: Member, Editorial Board, Journal of Biological Chemistry
1994 - 97: Section Editor, Journal of Immunology
1997 - 2002: Member, Allergy, Immunology and Transplantation Research
Committee, NIAID
1998 - 2004 Associate Editor, American Journal of Medicine
2001 Editor (with D. Stites. A. Terr, T. Parslow) Medical Immunology,
10th Ed. McGraw Hill
2001: Association of American Physicians
2004 Editor (with J. Stone, D. Hellmann) Current Rheumatology Diagnosis
& Treatment, 1st Ed. McGraw Hill, 2004
Selected
Peer-Reviewed Publications
1. Imboden JB: Innate immunity: turning off natural killing. Current
Biology, 6:1070-1072, 1996.
2. Shi J, Cinek T, Truitt KE, and Imboden JB: Wortmannin, an inhibitor
of phosphatidylinositol 3-kinase, blocks antigen-mediated, but not
CD3 monoclonal antibody-mediated activation of murine CD4+ T cells.
J. Immunol., 158:4688-4695, 1997.
3. Daikh D, Wofsy D, and Imboden JB, The CD28-B7 co-stimulatory
pathway and its role in autoimmune disease. J. Leuk. Biol. 62: 156-162,
1997.
4. Weber JR, Ostravik S, Torgersen KM, Danbolt NC, Berg SF, Ryan
JC, Tasken K, Imboden JB and Vaage JT, Molecular cloning of the
cDNA encoding pp36, a tyrosine-phosphorylated adaptor protein selectively
expressed by T cells and natural killer cells. J. Exp. Med. 187:
1157-1161, 1998.
5. Barz C, Nagel T, Truitt K, and Imboden JB, Mutational analysis
of CD28-mediated co-stimulation of Jun N-terminal kinase and interleukin-2
production. J. Immunol., 161: 5366-5372, 1998.
6. Sadra A, Cinek T, Arellano JL, Truitt KE, and Imboden JB, Identification
of tyrosine phosphorylation sites in the CD28 cytoplasmic domain
and their role in the co-stimulation of Jurkat T-cells. J. Immunol.
162: 1966-1973, 1999.
7. Cinek, T, Sadra A, and Imboden JB, Tyrosine-independent transmission
of inhibitory signals by CTLA-4. J. Immunol., 164: 5-8, 2000.
8. Chikuma S, Cinek T, Imboden JB, and Bluestone JA, Negative Regulation
of T Cell Receptor-Lipid Raft interaction by Cytotoxic T Lymphocyte
Associated Antigen-4. J. Exp. Med. 197:129-135, 2003.
9. Andres PG, Howland KC, Kane LP, Barron L, Sadra A, Imboden JB,
Weiss A, and Abbas AK, The mechanism of CD28-mediated T cell co-stimulation.
Nature Immunol. 5:435-442, 2004.
10. Sadra A, Cinek T, and Imboden JB, Translocation of CD28 to lipid
rafts and co-stimulation of interleukin-2 Proc Natl Acad Sci (USA)
101:11422-11427, 2004.
|
